Last reviewed · How we verify

panfotocoagulation (PASCAL)

University of Sao Paulo · FDA-approved active Small molecule

PASCAL (Pattern Scan Laser) delivers rapid, short-duration laser pulses to create a grid pattern of thermal burns on the retina, inducing photocoagulation to treat retinal diseases.

PASCAL (Pattern Scan Laser) delivers rapid, short-duration laser pulses to create a grid pattern of thermal burns on the retina, inducing photocoagulation to treat retinal diseases. Used for Proliferative diabetic retinopathy, Retinal vein occlusion with neovascularization, Other retinal conditions requiring panretinal photocoagulation.

At a glance

Generic namepanfotocoagulation (PASCAL)
SponsorUniversity of Sao Paulo
Drug classLaser photocoagulation device
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

PASCAL is a laser-based technology that performs panretinal photocoagulation through a scanning pattern delivery system, creating multiple small burns across the retina in a single session. This approach aims to reduce treatment time and improve patient comfort compared to traditional continuous-wave photocoagulation while achieving similar therapeutic outcomes by destroying abnormal retinal tissue and reducing hypoxia-driven neovascularization.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results